Market Cap 409.68B
Revenue (ttm) 56.33B
Net Income (ttm) 4.28B
EPS (ttm) N/A
PE Ratio 24.29
Forward PE 21.55
Profit Margin 7.59%
Debt to Equity Ratio -26.45
Volume 5,921,000
Avg Vol 6,281,506
Day's Range N/A - N/A
Shares Out 1.77B
Stochastic %K 9%
Beta 0.50
Analysts Strong Sell
Price Target $244.54

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 847 932 7900
Address:
1 North Waukegan Road, North Chicago, United States
Czreri1
Czreri1 Nov. 26 at 10:35 PM
$ABBV why is this dropping every day.
0 · Reply
BrettAshcroftGreenSA
BrettAshcroftGreenSA Nov. 26 at 8:59 PM
0 · Reply
mark90
mark90 Nov. 26 at 6:25 PM
$ABBV Very low volume.
0 · Reply
Buzzdaq
Buzzdaq Nov. 26 at 5:20 PM
$ABBV Dec5 235c (.96)
0 · Reply
ZacksResearch
ZacksResearch Nov. 26 at 4:23 PM
Which pharma giant is better positioned heading into 2026 — $ABBV or $PFE? ABBV’s surging immunology sales and its smoother LOE path are the clear standouts as both companies move toward a pivotal 2026. Full breakdown here 👉 https://www.zacks.com/stock/news/2796033/abbvie-and-pfizer-a-closer-look-at-two-pharma-heavyweights?cid=sm-stocktwits-2-2796033-teaser-22598&ADID=SYND_STOCKTWITS_TWEET_2_2796033_TEASER_22598
1 · Reply
ZacksResearch
ZacksResearch Nov. 26 at 3:23 PM
$ABBV vs. $PFE: Which Pharma Giant Wins the Growth Battle? 💊 AbbVie is overcoming Humira's LOE with strong sales from Skyrizi & Rinvoq, expecting mid-single-digit revenue growth in 2025 with a high single-digit CAGR through 2029. Meanwhile, Pfizer faces a challenging LOE cliff impacting revenues from 2026-2030, despite expected 6% CAGR in revenues from 2025 to 2030. Discover why ABBV might be the stronger pick for growth-focused investors 👉 https://www.zacks.com/stock/news/2796033/abbvie-and-pfizer-a-closer-look-at-two-pharma-heavyweights?cid=sm-stocktwits-2-2796033-body-22585&ADID=SYND_STOCKTWITS_TWEET_2_2796033_BODY_22585
1 · Reply
TruthBroker2
TruthBroker2 Nov. 26 at 2:52 PM
0 · Reply
BrettAshcroftGreenSA
BrettAshcroftGreenSA Nov. 26 at 2:28 PM
Dividends are real. The price drop on payout day doesn’t change earnings, which means valuation improves. That’s why funds like $SCHD matter — consistent dividend growers, strong ROE, solid free cash flow, and disciplined rebalancing. The fund is shifting toward undervalued Health Care names like $MRK $ABBV $BMY as the sector wakes up. With rates trending lower, qualified dividends become more attractive vs. cash yields. $SCHD sits near 10-year-high starting yields while REITs, MLPs, and staples trade at big discounts. Dividend value is back on sale. https://seekingalpha.com/article/4847759-schd-why-dividends-are-real
0 · Reply
TruthBroker2
TruthBroker2 Nov. 26 at 1:13 PM
0 · Reply
Quantumup
Quantumup Nov. 26 at 12:22 PM
Cantor reit'd $VERA Overweight-$100/said—We continue to view VERA shares as undervalued ($1.8B mkt cap with $497M cash as of Sep 30), given the competitive profile in lgAN, a multi-$B market that can easily accommodate multiple disease-modifying B cell modulators. $OTSKY $JBIO $ALNY $ABBV VRTX NVS IONS Cantor additionally said: This view is in line with that of multiple investors we spoke to at ASN who believe IgAN is a >$10B market for B-cell modulators. Our math suggests IgAN patients with proteinuria ≥0.5 g/day (76% according to literature (here)) represent 85K-151K US patients. Assuming annualized Tarpeyo pricing (~$180K), this subgroup alone could represent a market opportunity >$15B.
0 · Reply
Latest News on ABBV
5 Dividend Stocks to Hold for the Next 10 Years

Nov 24, 2025, 7:25 AM EST - 2 days ago

5 Dividend Stocks to Hold for the Next 10 Years

ARCC ENB O VZ


AbbVie Stock Falls 4% -- What Investors Need to Know

Nov 17, 2025, 7:17 AM EST - 9 days ago

AbbVie Stock Falls 4% -- What Investors Need to Know


2 Strong Healthcare Stock Picks for Dividend Investors

Nov 13, 2025, 3:55 AM EST - 13 days ago

2 Strong Healthcare Stock Picks for Dividend Investors

JNJ


AbbVie Shares Rise To Intraday High After Key Trading Signal

Nov 12, 2025, 3:06 PM EST - 14 days ago

AbbVie Shares Rise To Intraday High After Key Trading Signal


AbbVie Has Many Bullish Attributes (Technical Analysis)

Nov 11, 2025, 10:40 PM EST - 15 days ago

AbbVie Has Many Bullish Attributes (Technical Analysis)


Three Healthcare Buys That Wall Street Loves

Nov 11, 2025, 10:50 AM EST - 15 days ago

Three Healthcare Buys That Wall Street Loves

AMGN LLY


5 Top Stocks to Buy in November

Nov 11, 2025, 8:49 AM EST - 15 days ago

5 Top Stocks to Buy in November


Healthcare Q3 Dividend Roundup: I Prefer AbbVie Over Pfizer

Nov 8, 2025, 6:38 AM EST - 18 days ago

Healthcare Q3 Dividend Roundup: I Prefer AbbVie Over Pfizer

PFE


3 Dividend Stocks Down 11%, 29%, and 41% to Buy in November

Nov 6, 2025, 8:45 AM EST - 20 days ago

3 Dividend Stocks Down 11%, 29%, and 41% to Buy in November

CL ZTS


My Favorite Dividend King to Buy in November

Nov 3, 2025, 7:30 AM EST - 23 days ago

My Favorite Dividend King to Buy in November


2 Magnificent Dividend Stocks to Buy and Hold Forever

Nov 2, 2025, 9:15 AM EST - 24 days ago

2 Magnificent Dividend Stocks to Buy and Hold Forever

ZTS


Best Dividend Aristocrats For November 2025

Nov 1, 2025, 10:25 AM EDT - 25 days ago

Best Dividend Aristocrats For November 2025

ABT ADM ADP AMCR AOS ATO BDX


Why AbbVie Stock Flopped on Friday

Nov 1, 2025, 6:15 AM EDT - 25 days ago

Why AbbVie Stock Flopped on Friday


AbbVie Inc. (ABBV) Q3 2025 Earnings Call Transcript

Oct 31, 2025, 3:56 PM EDT - 26 days ago

AbbVie Inc. (ABBV) Q3 2025 Earnings Call Transcript


AbbVie: Why Q3 Confirms Its Immunology Dominance

Oct 31, 2025, 10:39 AM EDT - 26 days ago

AbbVie: Why Q3 Confirms Its Immunology Dominance


AbbVie Lifts Profit Outlook as Sales Rise

Oct 31, 2025, 8:42 AM EDT - 26 days ago

AbbVie Lifts Profit Outlook as Sales Rise


AbbVie Reports Third-Quarter 2025 Financial Results

Oct 31, 2025, 7:49 AM EDT - 26 days ago

AbbVie Reports Third-Quarter 2025 Financial Results


Best Dividend Kings: October 2025

Oct 29, 2025, 5:11 AM EDT - 4 weeks ago

Best Dividend Kings: October 2025

ABM ABT ADM ADP AWR BDX BKH


AbbVie: Deep Discount Before Earnings

Oct 28, 2025, 11:28 AM EDT - 4 weeks ago

AbbVie: Deep Discount Before Earnings


Czreri1
Czreri1 Nov. 26 at 10:35 PM
$ABBV why is this dropping every day.
0 · Reply
BrettAshcroftGreenSA
BrettAshcroftGreenSA Nov. 26 at 8:59 PM
0 · Reply
mark90
mark90 Nov. 26 at 6:25 PM
$ABBV Very low volume.
0 · Reply
Buzzdaq
Buzzdaq Nov. 26 at 5:20 PM
$ABBV Dec5 235c (.96)
0 · Reply
ZacksResearch
ZacksResearch Nov. 26 at 4:23 PM
Which pharma giant is better positioned heading into 2026 — $ABBV or $PFE? ABBV’s surging immunology sales and its smoother LOE path are the clear standouts as both companies move toward a pivotal 2026. Full breakdown here 👉 https://www.zacks.com/stock/news/2796033/abbvie-and-pfizer-a-closer-look-at-two-pharma-heavyweights?cid=sm-stocktwits-2-2796033-teaser-22598&ADID=SYND_STOCKTWITS_TWEET_2_2796033_TEASER_22598
1 · Reply
ZacksResearch
ZacksResearch Nov. 26 at 3:23 PM
$ABBV vs. $PFE: Which Pharma Giant Wins the Growth Battle? 💊 AbbVie is overcoming Humira's LOE with strong sales from Skyrizi & Rinvoq, expecting mid-single-digit revenue growth in 2025 with a high single-digit CAGR through 2029. Meanwhile, Pfizer faces a challenging LOE cliff impacting revenues from 2026-2030, despite expected 6% CAGR in revenues from 2025 to 2030. Discover why ABBV might be the stronger pick for growth-focused investors 👉 https://www.zacks.com/stock/news/2796033/abbvie-and-pfizer-a-closer-look-at-two-pharma-heavyweights?cid=sm-stocktwits-2-2796033-body-22585&ADID=SYND_STOCKTWITS_TWEET_2_2796033_BODY_22585
1 · Reply
TruthBroker2
TruthBroker2 Nov. 26 at 2:52 PM
0 · Reply
BrettAshcroftGreenSA
BrettAshcroftGreenSA Nov. 26 at 2:28 PM
Dividends are real. The price drop on payout day doesn’t change earnings, which means valuation improves. That’s why funds like $SCHD matter — consistent dividend growers, strong ROE, solid free cash flow, and disciplined rebalancing. The fund is shifting toward undervalued Health Care names like $MRK $ABBV $BMY as the sector wakes up. With rates trending lower, qualified dividends become more attractive vs. cash yields. $SCHD sits near 10-year-high starting yields while REITs, MLPs, and staples trade at big discounts. Dividend value is back on sale. https://seekingalpha.com/article/4847759-schd-why-dividends-are-real
0 · Reply
TruthBroker2
TruthBroker2 Nov. 26 at 1:13 PM
0 · Reply
Quantumup
Quantumup Nov. 26 at 12:22 PM
Cantor reit'd $VERA Overweight-$100/said—We continue to view VERA shares as undervalued ($1.8B mkt cap with $497M cash as of Sep 30), given the competitive profile in lgAN, a multi-$B market that can easily accommodate multiple disease-modifying B cell modulators. $OTSKY $JBIO $ALNY $ABBV VRTX NVS IONS Cantor additionally said: This view is in line with that of multiple investors we spoke to at ASN who believe IgAN is a >$10B market for B-cell modulators. Our math suggests IgAN patients with proteinuria ≥0.5 g/day (76% according to literature (here)) represent 85K-151K US patients. Assuming annualized Tarpeyo pricing (~$180K), this subgroup alone could represent a market opportunity >$15B.
0 · Reply
ColinWolf981
ColinWolf981 Nov. 26 at 9:12 AM
$ABBV remains active in healthcare. AMBR will provide its Q3 results and corporate update via webcast November 26. https://viavid.webcasts.com/starthere.jsp?ei=1743886&tp_key=bebae2bd4a
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Nov. 26 at 5:57 AM
Enter: $ABBV Calls Strike Price: $230 Expiry Date: DEC 19 2025 Buy in Price: $5.95 - $6.15 Sell Price: $10.41 Profit : +75% (Turn every $1 into $1.75) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
WaveRB77
WaveRB77 Nov. 26 at 2:17 AM
$ABBV green candle that's a hammer .Prices spike tomorrow.
0 · Reply
HedgeAlerts
HedgeAlerts Nov. 26 at 1:56 AM
Hedge Alert Live - Protect Your Portfolio Contract: $ABBV $230.00 Put · DEC 05, 2025 Exp Entry Price: $2.53 - $2.83 Exit Price Target: $5.09 Profit Margin: +101% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
Iightning
Iightning Nov. 25 at 11:58 PM
1ightning® Options Trade Alert (Actionable) | Buy $ABBV Dec 5 $230 Call | Enter: $3.91 Exit: $6.31 | Profit: 61.20% ROI | https://1ightning.com
0 · Reply
TruthBroker2
TruthBroker2 Nov. 25 at 7:22 PM
0 · Reply
dogDazeSummer
dogDazeSummer Nov. 25 at 7:07 PM
$BIIB strikes again $50M up front. This time with an oral with “biological effect” https://www.biopharmadive.com/news/biogen-dayra-therapeutics-immunology-macrocyclic-peptides-versant-ventures/806269/ “The deal with Dayra centers around its oral macrocyclic peptides, which the company said have the “potential to offer biologic-like efficacy and safety in an oral format” compared to common infusion or injection immunology drugs. The molecules can also selectively target proteins associated with certain diseases, unlike traditional small molecule drugs that may have off-target effects.” $IFRX $ABBV
1 · Reply
Golden_Triangle_Capital
Golden_Triangle_Capital Nov. 25 at 6:41 PM
$HALO Is $ABBV a potential buyer for $HALO?? I'm hearing rumblings...
0 · Reply
LionsFan777
LionsFan777 Nov. 25 at 5:37 PM
$ABBV showing support at $230. I'm adding to my Jan 240 Calls.
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Nov. 25 at 1:24 PM
Results list 11/2025 out of 1341 calls 978 hit or over pass targets for 70.2% Accuracy. Cycle Trading Signal plugged into AI 🔥 lists 🔥 there is nothing out there more accurate 🔥 🔥 List 12/2025 is out 🔥 for trading with more accuracy 🔥 $A $AAPL $ABBV $AAMI $AAOI 🔥
0 · Reply
Iightning
Iightning Nov. 25 at 10:09 AM
1ightning® Options Trade Alert (Actionable) | Buy $ABBV Dec 5 $230 Call | Enter: $3.91 Exit: $6.31 | Profit: 61.20% ROI | https://1ightning.com
0 · Reply
LiquidThetaOptions
LiquidThetaOptions Nov. 25 at 7:57 AM
💎 LiquidTheta® Live Actionable Trade Asset: $ABBV Contracts: $ABBV December 18, 2026 $230 Calls Scale in: $23.77- $29.05 Scale out: $92.44-$158.46 Profit Potential : 184% ROI Blended Join 💎 Here: https://liquidtheta.com
0 · Reply